百时美施贵宝Bristol Myers Squibb Co. (BMY) 2022年年度报告「NYSE」.pdf

1、2022 Annual ReportOur MissionTo discover,develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the worlds leading biopharma company that transforms patients lives through scienceOur ValuesIntegrity|Innovation|Urgency|Passion|Accountability|Inclusion

2、 2023 Bristol-Myers Squibb Company.All rights reserved.for moderate to severe plaque psoriasis.All three of these medicines have the opportunity to change the standard of care for their respective diseases.We also expanded the potential of our new product portfolio through significant clinical miles

3、tones throughout the course of the year.We achieved positive top-line results for Reblozyl in first-line myelodysplastic syndromes and Abecma in the KarMMa-3 trial,which demonstrated superiority to standard regimens in relapsed and refractory multiple myeloma.Registrational trials were also initiate

4、d for Sotyktu in systemic lupus erythematosus,a disease with very high unmet medical need.We also made meaningful investments in our cell therapy franchise to expand manufacturing capacity and supply more product to patients.We continued to enhance our strong internal research and development capabi

5、lities with an extensive network of external collaborations.These include new strategic partnerships with Century and Immatics as well as the acquisition of Turning Point Therapeutics,which expanded our precision oncology portfolio.We augmented our existing artificial intelligence capabilities throu

6、gh a partnership with Owkin to further aid in the acceleration of drug design and development.2022 was an important year for our company,one with significant clinical and regulatory achievements that broadened our portfolio,advanced our pipeline and,importantly,delivered innovative new medicines to